Leukemia

PureTech Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Monday, December 12, 2022
Science, Other Science, Biotechnology, Research, Oncology, General Health, Health, Clinical Trials, Therapy, Apoptosis, Immune system, Immunodeficiency, Mab, U.S. FDA, Environment, National Cancer Institute, Society, Leukemia, Patient, DNA, Annual report, Research, PRTC, Death, American Society of Hematology, PD-1, PureTech Health, FDA, LSE, DNA repair, Drug development, Tislelizumab, Cancer, Annual general meeting, Survival, Lymphatic system, Colorectal cancer, AML, Multimedia, Clinical trial, Cell death, Safety, Acute myeloid leukemia, Cholangiocarcinoma, Toxicity, ASH, Immunoglobulin G, Neoplasm, Vaccine, Pharmaceutical industry, Venetoclax

The data were shared in a scientific poster presented at the American Society of Hematology (ASH) 64th Annual Meeting.

Key Points: 
  • The data were shared in a scientific poster presented at the American Society of Hematology (ASH) 64th Annual Meeting.
  • It is also in development as a treatment for a range of cancer indications with otherwise poor survival rates.
  • The data demonstrate the role of galectin-9 in multiple types of leukemia and the ability of anti-galectin-9 antibodies to provide effective anti-tumor activity in these cancers.
  • The National Cancer Institute estimates that about 61,000 new cases of leukemia are diagnosed each year, including about 20,000 in AML.

Orca Bio Presents Encouraging Interim Clinical Data on Orca-Q in Haploidentical Allogeneic Hematopoietic Stem Cell Transplants at 64th ASH Annual Meeting

Retrieved on: 
Monday, December 12, 2022
Biotechnology, Other Health, Health, Clinical Trials, Oncology, CD34, Literature, Physician, City, Lymphatic system, Microdeletion syndrome, Acute leukemia, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HLA, Society, Haematopoietic system, Patient, Cancer, Graft-versus-host disease, ALL, Division, Degenerative disease, Incidence, Acute lymphoblastic leukemia, Quality of life, Bio, Survival, AML, Clinical trial, MDS, Acute myeloid leukemia, CML, Toxic epidermal necrolysis, Blood, ASH, GRFS, Risk, Pharmaceutical industry, Dentistry, Vaccine, Killer whale, Hematology, Leukemia

Unlike standard of care haploidentical allogeneic hematopoietic stem transplant (alloHSCT), Orca-Q does not require post-transplant cyclophosphamide (PTCy).

Key Points: 
  • Unlike standard of care haploidentical allogeneic hematopoietic stem transplant (alloHSCT), Orca-Q does not require post-transplant cyclophosphamide (PTCy).
  • Orca-Q is an investigational high-precision cell therapy that is a proprietary composition of enriched CD34+ stem cells combined with specific T cell subsets.
  • Orca-Q is Orca Bios second investigational high-precision allogeneic cellular therapy to enter clinical development for hematological malignancies.
  • Orca Bio is a late-stage biotechnology company developing purified, high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders.

Ajax Therapeutics Presents Preclinical Data on AJ1-10502, a Next Generation Type II JAK2 Inhibitor, at the American Society of Hematology Annual Meeting

Retrieved on: 
Monday, December 12, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Health Technology, Clinical Trials, Therapy, Pancreatic serous cystadenoma, Spleen, MD, Poster, Doctor of Philosophy, Drug discovery, Society, Research, MPN, Patient, Translational research, MSK, Ajax, Myeloproliferative neoplasm, Memorial Sloan Kettering Cancer Center, Type, Type 2, Disease, Reticulocyte, JAK2, Bone marrow, Senior, Computational chemistry, Hematocrit, Secondary research, ASH, Pharmaceutical industry, Primary myelofibrosis, Leukemia

In preclinical studies, investigational Type II JAK2 inhibitors have been shown to overcome disease persistence to ruxolitinib and, most significantly, reduce mutant JAK2 allele burden that drives MPN disease progression.

Key Points: 
  • In preclinical studies, investigational Type II JAK2 inhibitors have been shown to overcome disease persistence to ruxolitinib and, most significantly, reduce mutant JAK2 allele burden that drives MPN disease progression.
  • Were very encouraged by the first preclinical data on our Type II JAK2 inhibitor program being presented today at the ASH Annual Meeting, said Craig E. Masse, PhD, Senior Vice President, Discovery Research at Ajax Therapeutics.
  • This data supports our findings that Type II JAK2 inhibitors can significantly reduce the mutant allele burden that drives MPNs which is not observed with Type I JAK2 inhibitors, such as ruxolitinib.
  • Ajax Therapeutics , Inc. is pursuing uniquely selective approaches to develop novel first-in-class therapeutics for myeloproliferative neoplasms (MPNs), including Myelofibrosis.

Precision BioSciences Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting

Retrieved on: 
Saturday, December 10, 2022
Oncology, Health, Infectious Diseases, Genetics, Other Health, Clinical Trials, Biotechnology, Genome, DLBCL, Infection, Dana–Farber Cancer Institute, Intellectual property, Leukemia, Society, NHL, Privacy, Follicular lymphoma, Research, Gene editing, Epidemiology, B-cell lymphoma, SEC filing, COVID-19, Growth, CAR, Neurotoxicity, Lymphatic system, CD19, Safety, DOI, CD4, Medical director, Pharmacokinetics, Insurance, Vaccine, Pharmaceutical industry, Security (finance), Patient

Autologous CAR T therapy remains one of the most promising approaches in the treatment of hematological malignancies.

Key Points: 
  • Autologous CAR T therapy remains one of the most promising approaches in the treatment of hematological malignancies.
  • Unlike autologous CAR T cell therapy, all allogeneic CAR T products are cryopreserved, which may alter the effective dose and composition of the post-thaw product.
  • The analysis found that CAR T expansion, a key determinant of durable response, strongly correlated with non-apoptotic CAR T cell dose.
  • These results indicate that the post-thaw CAR T product composition drives in vivo cell expansion potential and CAR T-related adverse events.

Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial

Retrieved on: 
Saturday, December 10, 2022
Health, FDA, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Genome, Pneumonia, University of Colorado School of Medicine, Society, Toxicity, Aplastic anemia, Disease, Government, Patient, COVID-19, AML, ELN, Gene, Anxiety, Phenotype, Associate, Diagnosis, Rash, Șaeș, DiNardo, Arsenic trioxide, Clinical trial, University, Toxic leukoencephalopathy, Acute promyelocytic leukemia, Security (finance), Webcast, The New England Journal of Medicine, Leukemia, Cough, CRi, European, Workforce, ASH, RARA, IWG, Freedom, Salvage therapy, CR, Elevated railway, Annual report, Compte rendu, Blood, Safety, CDK7, Acute myeloid leukemia, AES, Febrile neutropenia, Pharmaceutical industry, Medical device, Azacitidine, Syros, Venetoclax

As of October 13, 2022, eight newly diagnosed, unfit, RARA-positive patients had been enrolled in the trial, including six who were evaluable for response.

Key Points: 
  • As of October 13, 2022, eight newly diagnosed, unfit, RARA-positive patients had been enrolled in the trial, including six who were evaluable for response.
  • - Tamibarotene in combination with venetoclax and azacitidine administered at approved doses showed no evidence of increased toxicity relative to the doublet combination of venetoclax and azacitidine.
  • This includes rates of myelosuppression, which were comparable to reports with venetoclax and azacitidine in this population.
  • The randomized portion is expected to initiate in Q1 2023, with data expected in 2023 or 2024.

Global Fluorescent in Situ Hybridization Probe Market Report to 2027: Featuring Thermo Fisher Scientific, Roche Holdings, PerkinElmer and Sysmex Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, December 9, 2022
Genetics, Health, Oncology, IVD, Autism, Environment, Microdeletion syndrome, Diagnosis, Leukemia, Research, Non-functional testing, Birth, Disability in Canada, Incidence, Cancer, Government, Growth, Flow-FISH, Ageing, Application, Medical device, Medical imaging, FISH

In 2021, instrument/ software segment held a major share in the market.

Key Points: 
  • In 2021, instrument/ software segment held a major share in the market.
  • By Technology: The report provides the bifurcation of the market into three segments based on the technology: Q FISH, Flow FISH and others.
  • In 2021, Q FISH technology segment held a major share in the market.
  • By Application: The report provides the bifurcation of the market into two segments based on the application: cancer diagnostics and other.

ImmunoGen Announces Clinical Collaboration with Gilead to Evaluate Pivekimab Sunirine in Combination with Magrolimab in Relapsed/Refractory Acute Myeloid Leukemia

Retrieved on: 
Friday, December 9, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Security (finance), DLBCL, IMGN, ImmunoGen, Gilead Sciences, MD, Azacitidine, Leukemia, EMA, Orphan, Patient, DNA, Cancer, Toxicity, Follicular lymphoma, Anemia, Annual report, ADC, European Medicines Agency, Phagocytosis, CD47, Disease, FDA, Myelodysplastic syndrome, Macrophage, Acute leukemia, COVID-19, BPDCN, IGN, Death, Breakthrough therapy, AML, Lymphatic system, Bone marrow, Safety, Senior, Control, MDS, Acute myeloid leukemia, Infection, Blastic plasmacytoid dendritic cell neoplasm, Hematological Cancer Research Investment and Education Act, Pharmaceutical industry, Vaccine

Expected to initiate in 2023, the collaboration will be a new cohort in ImmunoGen's 802 study and will evaluate pivekimab in combination with magrolimab in up to 42 patients with R/R CD123-positive AML.

Key Points: 
  • Expected to initiate in 2023, the collaboration will be a new cohort in ImmunoGen's 802 study and will evaluate pivekimab in combination with magrolimab in up to 42 patients with R/R CD123-positive AML.
  • Pivekimab sunirine is a CD123-targeting ADC in clinical development for hematological malignancies, including blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML), and other CD123+ hematologic malignancies.
  • Pivekimab is currently being evaluated as monotherapy for patients with BPDCN and in combination with Vidaza (azacitidine) and Venclexta (venetoclax) for patients with untreated and relapsed/refractory AML.
  • The European Medicines Agency (EMA) granted orphan drug designation to pivekimab for the treatment of BPDCN in June 2020.

Ajax Therapeutics Appoints Srdan “Serge” Verstovsek, MD, PhD, to Scientific Advisory Board

Retrieved on: 
Tuesday, December 6, 2022
Oncology, Health, Health Technology, Research, Science, Pharmaceutical, Biotechnology, Therapy, Pancreatic serous cystadenoma, Srđan, MD, Doctor of Philosophy, Drug discovery, Society, Research, MPN, Patient, Translational research, Section, International Work Group for Indigenous Affairs, MD Anderson Cancer Center, MSK, Ajax, Memorial Sloan Kettering Cancer Center, Myeloproliferative neoplasm, Division, Executive Committee, School of Dental Medicine, University of Zagreb, Committee, JAK2, American Society for Clinical Investigation, University, Computational chemistry, SAB, Pharmaceutical industry, Primary myelofibrosis, Leukemia

Ajax Therapeutics, Inc., a biopharmaceutical company applying computational chemistry and structure-based technologies to develop novel small molecules for myeloproliferative neoplasms (MPNs), today announced the appointment of Srdan Serge Verstovsek, MD, PhD, to the Companys Scientific Advisory Board (SAB).

Key Points: 
  • Ajax Therapeutics, Inc., a biopharmaceutical company applying computational chemistry and structure-based technologies to develop novel small molecules for myeloproliferative neoplasms (MPNs), today announced the appointment of Srdan Serge Verstovsek, MD, PhD, to the Companys Scientific Advisory Board (SAB).
  • I am pleased to be joining the Ajax SAB at this exciting stage of the companys development, said Dr. Verstovsek.
  • Ajax Therapeutics, Inc. is pursuing uniquely selective approaches to develop novel first-in-class therapeutics for myeloproliferative neoplasms (MPNs), including Myelofibrosis.
  • NOTE: Dr. Ross Levine serves on the board of directors of, has provided advisory services for, and has equity interests in Ajax Therapeutics.

Global Brands Lean on Business Spend Management to Bolster Resilience

Retrieved on: 
Wednesday, December 14, 2022
Spend, IPO, BSM, Bowery, HSBC, UPS, Leukemia, Automation, ESG, LLS, Uber, Diageo, AstraZeneca, Uncertainty, Treasury, Growth, Multimedia, Leukemia & Lymphoma Society, J. R. Miller, SAN, Organization, Video game, Management, Coupa

SAN MATEO, Calif., Dec. 14, 2022 /PRNewswire/ -- Leading global brands are relying on Business Spend Management (BSM) to build resilience into their organizations, sharing inspiring stories, insights, and successes of their transformations during Coupa Software's (NASDAQ: COUP) 2022 Executive Summit Series. The series brought together more than 500 executives across Australia, Singapore, France, U.K., and the U.S.

Key Points: 
  • SAN MATEO, Calif., Dec. 14, 2022 /PRNewswire/ --Leading global brands are relying on Business Spend Management (BSM) to build resilience into their organizations, sharing inspiring stories, insights, and successes of their transformations during Coupa Software 's (NASDAQ: COUP) 2022 Executive Summit Series.
  • "In the last three years, LLS has freed up $18.4 million through smarter business spending through Coupa that we've invested in lifesaving programs.
  • Coupa is the cloud-based Business Spend Management (BSM) platform that unifies processes across supply chain, procurement, and finance functions.
  • Coupa empowers organizations around the world to maximize value and operationalize purpose through their business spend.

Treadwell Therapeutics Announces A Presentation at the 2022 ASH Annual Meeting Featuring a Clinical Trial Update on CFI-400945, an oral PLK4 inhibitor

Retrieved on: 
Tuesday, December 13, 2022
Therapy, Poster, IWG, MD, Society, Leukemia, HPK1, Science, TCR, Cancer, Decitabine, MD Anderson Cancer Center, Acute myeloid leukemia, TP53, Treadwell, Multicenter Automatic Defibrillator Implantation Trial, Division, AE, Azacitidine, TTK, Chronic myelomonocytic leukemia, AML, Myelodysplastic syndrome, PLK4, ELN, Toxic leukoencephalopathy, ASH, AES, PD, Febrile neutropenia, Pharmaceutical industry, Tolerability, Safety, Patient

The poster presentation described the preliminary results from the monotherapy dose optimization portion of the TWT-202 in advanced leukemias.

Key Points: 
  • The poster presentation described the preliminary results from the monotherapy dose optimization portion of the TWT-202 in advanced leukemias.
  • "CFI-400945 had previously shown single agent complete remissions in refractory high risk AML.
  • Treadwell Therapeutics is a science driven, clinical-stage, multi-modality biotechnology company developing first-in-class and best-in-class medicines to address unmet needs in patients with cancer.
  • The Company's internally developed clinical pipeline includes CFI-400945, CFI-402257 (TTK inhibitor) and CFI-402411 (HPK1 inhibitor).